Subscribe

Beijing Health (Holdings) Limited (2389.HK)

HKD0.08 +0.00 (+0.00%)
HK HKSE Healthcare Medical - Healthcare Information Services
Address Unit 2704
Hong Kong, HK
CEO Xue Heng Liu
IPO 2002-04-26
ISIN KYG0957Q1082

Explore sections of this company profile

Description

Beijing Health (Holdings) Limited, an investment holding company, provides medical, health, and geriatric care related services and products in the People’s Republic of China. It engages in the investment and operation of general health industrial park and incubator projects; sports businesses, which includes construction and operation of stadiums for winter sports; and investment in the field of the biotechnology, pharmaceutical, medical services, and medical travel. The company also provides investment management consulting services; and engages in trading geriatric care related furniture. In addition, it is involved in medical and logistics related property development activities. The company was formerly known as Beijing Enterprises Medical and Health Industry Group Limited and changed its name to Beijing Health (Holdings) Limited in June 2021. Beijing Health (Holdings) Limited was founded in 1995 and is headquartered in Cheung Sha Wan, Hong Kong.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD0.08 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
853.0K
Beta
-0.15
Float Shares
2.55B
Free Float %
42.1%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.54% +1.54% +1.54% -4.35% -12.00% +3.13% -18.52% -35.29% -37.14% -87.55% -97.42%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.08
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
0.61
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
  • Revenue growth Medical - Healthcare Information Services: +14.2%
    +4.8% Q4'25: +29.4% (vs Q4'23)
  • EPS growth Medical - Healthcare Information Services: +43.1%
    +13.0% Q4'25: -55.3% (vs Q4'23)
  • FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%
    -61.8% Q4'25: -44.5% (vs Q4'23)
  • EBIT margin Medical - Healthcare Information Services: +8.8%
    -63.0% Q4'25: -29.7% (vs Q4'23)
  • ROIC Medical - Healthcare Information Services: +5.2%
    -6.1% Q4'25: -5.9% (vs Q4'23)
  • Share dilution Medical - Healthcare Information Services: -0.1%
    +0.0% Q4'25: +0.0% (vs Q4'23)
  • Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×
    -1.47× Q4'25: -1.30× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.14) × ERP
WACC = 78% × Ke + 22% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 0.08
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2018
actual
Dec 2019
actual
Dec 2025
actual
Dec 2026
1 Rev. Ana.
1 EPS Ana.
Revenue
178.89M
est: 198.87M (-10.0%)
200.76M
est: 303.79M (-33.9%)
157.20M
est: 198.87M (-21.0%)
303.79M
303.79M – 303.79M
+52.8% YoY
EBITDA
116.92M
est: -90.98M (+228.5%)
-436.49M
est: -138.99M (-214.0%)
-77.41M
est: -77.96M (+0.7%)
-119.10M
-119.10M – -119.10M
-52.8% YoY
EBIT
104.01M
est: -123.66M (+184.1%)
-451.99M
est: -188.91M (-139.3%)
-99.09M
est: -108.96M (+9.1%)
-166.44M
-166.44M – -166.44M
-52.8% YoY
Net Income
43.45M
est: 8.97M (+384.2%)
-422.39M
est: 68.81M (-713.9%)
-100.91M
est: 8.97M (-1,224.6%)
68.81M
68.81M – 68.81M
+666.8% YoY
SGA
235.13M
est: 107.81M (+118.1%)
173.21M
est: 164.69M (+5.2%)
95.15M
est: 96.91M (-1.8%)
148.04M
148.04M – 148.04M
+52.8% YoY
EPS
0.01
est: 0.00 (+386.2%)
-0.07
est: 0.01 (-712.8%)
-0.02
est: 0.00 (-1,227.6%)
0.01
0.01 – 0.01
+666.8% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-27 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-26 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-22 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-21 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-20 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-19 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-18 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-15 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-14 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-13 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-12 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-11 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-08 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-07 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-06 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-05 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-04 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-04-30 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-29 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-28 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-27 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-24 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-21 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-20 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-17 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-16 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-66.38M
OE per share TTM
-0.01
Owner's Yield
-16.60%
Maintenance CapEx ratio
Maint CapEx / Avg PPE
545.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
Total invested
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-478.7K
Shares Outstanding
6.06B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Shi Xing Zhu Executive Chairman of the Board 3M male
Shan Chao Gu Executive Director 3M male
Zheng Chun Wang Executive Director 3M male
Xue Heng Liu Chief Executive Officer & Executive Director 1M male
Ka Tak Lam Chief Financial Officer, Financial Controller & Company Secretary male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits